6.92 USD
▲+0.03+2.37%
盘后 6.87 +1.63%
2026-08-03
市值
$28.01M
市盈率
0.17
EPS
40.45
股息率
—
52 周区间
6.32 – 12.60
成交量
8.79K
Beta
0.97
目标价
39.00
52W 低 6.3252W 高 12.60
价格走势
公司简介
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ...